These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 28700554)

  • 1. Faster, deeper, smaller-the rise of antibody-like scaffolds.
    Owens B
    Nat Biotechnol; 2017 Jul; 35(7):602-603. PubMed ID: 28700554
    [No Abstract]   [Full Text] [Related]  

  • 2. Rush to protect lucrative antibody patents kicks into gear.
    Ledford H
    Nature; 2018 May; 557(7707):623-624. PubMed ID: 29844545
    [No Abstract]   [Full Text] [Related]  

  • 3. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors. A new drug class for the treatment of hypercholesterolemia.
    Ortega Martínez de Victoria E
    Endocrinol Diabetes Nutr; 2017; 64(7):341-344. PubMed ID: 28745604
    [No Abstract]   [Full Text] [Related]  

  • 4. Inhibition of proprotein convertase subtilisin/kexin type 9 in the treatment of hypercholesterolemia.
    Ascaso JF
    Endocrinol Nutr; 2016; 63(6):255-7. PubMed ID: 27050861
    [No Abstract]   [Full Text] [Related]  

  • 5. Engineering antibodies for clinical applications.
    Jain M; Kamal N; Batra SK
    Trends Biotechnol; 2007 Jul; 25(7):307-16. PubMed ID: 17512622
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antibody engineering and therapeutics conference. The annual meeting of the antibody society, Huntington Beach, CA, December 7-11, 2014.
    Larrick JW; Parren P; Huston JS; Plückthun A; Bradbury A; Tomlinson IM; Chester KA; Burton DR; Adams GP; Weiner LM; Scott JK; Alfenito MR; Veldman T; Reichert JM
    MAbs; 2014; 6(5):1115-23. PubMed ID: 25517297
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Modern Lipid therapy today and tomorrow: anti-PCSK9 : A magic bullet concept following Paul Ehrlich].
    Erbel R; Gitt AK
    Herz; 2016 Jun; 41(4):271-2. PubMed ID: 27241696
    [No Abstract]   [Full Text] [Related]  

  • 8. Engineering at the limits of antibody space.
    Huston JS
    Protein Eng Des Sel; 2013 Oct; 26(10):559-60. PubMed ID: 24077692
    [No Abstract]   [Full Text] [Related]  

  • 9. Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Brief Overview.
    Noel ZR; Beavers CJ
    Am J Med; 2017 Feb; 130(2):229.e1-229.e4. PubMed ID: 27751895
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Proprotein Convertase Subtilisin/Kexin Type 9 Monoclonal Antibodies for Acute Coronary Syndrome: A Narrative Review.
    Navarese EP; Kolodziejczak M; Kereiakes DJ; Tantry US; O'Connor C; Gurbel PA
    Ann Intern Med; 2016 May; 164(9):600-7. PubMed ID: 26999484
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reduction of cardiovascular risk with evolocumab (Repatha).
    Med Lett Drugs Ther; 2017 Apr; 59(1519):63-64. PubMed ID: 28419071
    [No Abstract]   [Full Text] [Related]  

  • 12. Engineering smart antibodies.
    Matsiko A
    Nat Mater; 2018 Apr; 17(4):295. PubMed ID: 29581574
    [No Abstract]   [Full Text] [Related]  

  • 13. The complexity of lipoprotein (a) lowering by PCSK9 monoclonal antibodies.
    Lambert G; Thedrez A; Croyal M; Ramin-Mangata S; Couret D; Diotel N; Nobécourt-Dupuy E; Krempf M; LeBail JC; Poirier B; Blankenstein J; Villard EF; Guillot E
    Clin Sci (Lond); 2017 Feb; 131(4):261-268. PubMed ID: 28108631
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intrabody-based strategies for inhibition of vascular endothelial growth factor receptor-2: effects on apoptosis, cell growth, and angiogenesis.
    Wheeler YY; Kute TE; Willingham MC; Chen SY; Sane DC
    FASEB J; 2003 Sep; 17(12):1733-5. PubMed ID: 12958192
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-vascular endothelial growth factor receptor-2 antibody accelerates renal disease in the NZB/W F1 murine systemic lupus erythematosus model.
    Watanabe H; Mamelak AJ; Weiss E; Wang B; Freed I; Brice AK; Wachtman L; Gabrielson KL; Yokota N; Hicklin DJ; Kerbel RS; Haas M; Sauder DN
    Clin Cancer Res; 2005 Jan; 11(1):407-9. PubMed ID: 15671573
    [No Abstract]   [Full Text] [Related]  

  • 16. Engineering antibody therapeutics.
    Chiu ML; Gilliland GL
    Curr Opin Struct Biol; 2016 Jun; 38():163-73. PubMed ID: 27525816
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protein engineering techniques for antibody humanization.
    Hurle MR; Gross M
    Curr Opin Biotechnol; 1994 Aug; 5(4):428-33. PubMed ID: 7765176
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition--The Dream of Translational Medicine.
    Uppugunduri CR; George M
    J Cardiovasc Pharmacol; 2016 Feb; 67(2):191-2. PubMed ID: 26398165
    [No Abstract]   [Full Text] [Related]  

  • 19. [Monoclonal antibodies against PCSK9: from bench to clinic].
    Guijarro Herraiz C
    Clin Investig Arterioscler; 2016 May; 28 Suppl 2():14-21. PubMed ID: 27888901
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CardioPulse: The European Medicines Agency's approval of proprotein convertase subtilisin/kexin type 9 inhibitors.
    Blind E; de Graeff PA; Meurs I; Holtkamp F; Baczynska A; Janssen H
    Eur Heart J; 2016 Feb; 37(6):502-3. PubMed ID: 26853264
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.